AR and prostate cancer: EPI-506 is an antagonist of the transcriptional regulatory region AF-1 (activation function-1) of the AR, a region present in the NTD of the receptor, and acts as an inhibitor of the growth of prostate cancer cells with aberrant AR activity, including cells with constitutively active AR-7 [208].